查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1855450

按品牌類型、用途、最終用戶、劑型和分銷管道分類的東莨菪鹼市場—2025-2032年全球預測

Hyoscine Market by Brand Type, Application, End User, Dosage Form, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，東莨菪鹼市場規模將達到 6.6805 億美元，複合年成長率為 4.76%。

關鍵市場統計數據
基準年 2024 4.6041億美元
預計年份：2025年 4.8218億美元
預測年份 2032 6.6805億美元
複合年成長率 (%) 4.76%

本文簡要說明了東莨菪鹼的臨床效用。不斷變化的製劑和供應鏈動態影響相關人員的優先事項和策略規劃。

東莨菪鹼在臨床上佔據獨特的地位，其應用範圍涵蓋預防暈動病、控制胃腸痙攣以及手術全期分泌物等。臨床醫師看重東莨菪鹼的抗膽鹼能特性，此特性能夠調節胃竇和胃腸道通路。同時，製劑研發人員和製藥公司也在不斷應對不斷變化的給藥技術、監管要求和通路動態。近年來，人們的關注點已從簡單的劑型轉向以患者為中心的方案，力求在療效、耐受性和便利性之間取得平衡。

隨著臨床實務日益重視門診治療和居家管理，東莨菪鹼在經皮治療中的重要性也日益凸顯。同時，透皮和控制釋放製劑的創新正在應對患者依從性方面的挑戰，並改善處方醫生所要求的療效。這些因素既為研發人員帶來了機遇，也帶來了責任，他們需要展現出始終如一的產品品質、完善的藥物安全檢測，並與不斷變化的支付方和醫院採購優先事項保持一致。因此，相關人員必須整合臨床、商業和監管方面的考量，才能保持競爭力。

從傳統供應鏈轉向更具韌性和多元化的網路轉型已成為一項策略要務。製造商和經銷商正在調整營運，以確保原料藥藥和包裝材料的持續供應。本引言透過重點闡述治療效用、製劑趨勢和供應端韌性之間的相互關係，為後續的總結奠定了基礎，這些關係共同構成了當前摘要市場格局。

技術進步、監管加強和分銷管道轉變如何重塑產品開發和競爭優勢的商業模式

由於技術、監管環境和醫療服務模式的變革，東莨菪鹼市場正在經歷顯著變化。對新型經皮吸收貼片設計和長效注射劑的研究反映了整個產業向緩釋性並減少全身性副作用。在產品創新的同時，監管機構也越來越重視生命週期資料、真實世界安全性監測和核准後監管，促使生產商加強對藥物安全檢測基礎設施和品質系統的投入。

在商業方面，分銷管道正在分散，數位藥房平台正在加速患者獲取藥物並改變購買行為，與此同時，合約開發和受託製造公司之間的整合正在重塑東莨菪鹼製劑的生產地點和方式，促進垂直整合和戰略夥伴關係，從而加快產品上市時間。

總而言之，這些趨勢正在改變競爭動態，使其從簡單的價格戰轉向以患者體驗、監管穩健性和供應彈性為重點的差異化產品。那些將創新與務實的監管和分銷策略相結合的公司，將能夠更好地掌握處方模式和醫療服務模式轉變所帶來的機會。

為因應美國關稅，策略性供應鏈調整和採購策略將推動整個價值鏈的多元化、近岸外包和韌性建設。

美國2025年推出的關稅政策和貿易措施給整個醫藥供應鏈帶來了壓力，尤其是那些依賴進口原料藥和特殊包裝的產品。這導致製造商重新調整籌資策略，力求在不影響產品品質或供應連續性的前提下，降低投入成本波動的影響。事實上，為了降低跨境關稅風險，製造商正在加速推動原料藥來源多元化、取得二手資訊以及評估近岸外包方案等工作。

此外，醫院和綜合醫療系統的採購團隊正在透過收緊合約條款和明確供應商評估標準來應對，同時考慮到潛在的成本轉嫁問題。這些措施正在推動商業團隊和供應鏈團隊之間更緊密的合作，並促進優先考慮供應連續性和合約彈性的情境規劃。同時，日益複雜的監管和海關事務促使製造商加強其文件和合規能力，從而降低因運輸延誤而導致庫存敏感型醫療機構營運中斷的風險。

重要的是，關稅環境提升了包裝和運輸創新技術的戰略價值，這些創新能夠減輕重量並減少對進口零件的依賴。投資於此類漸進式創新的企業能夠更好地抵禦貿易政策波動的影響。總體而言，2025 年關稅政策促進了供應鏈的策略性最佳化、供應商管治的加強以及韌性和營運靈活性的優先發展。

將品牌策略、臨床應用、終端用戶需求、劑型偏好和分銷管道動態與商業性成功聯繫起來的可操作細分洞察

細緻的市場區隔方法揭示了臨床需求、製劑創新和商業性重點的交匯點。按品牌類型分析表明，品牌藥和學名藥之間的差異驅動著不同的策略。品牌藥生產商強調透過新型給藥系統和增強的患者支援服務來實現差異化，而學名藥生產商則在成本、生產效率和分銷範圍方面競爭。從應用領域來看，胃腸道疾病管理和暈動病預防的需求各不相同，不同的處方醫生特徵、給藥方案和製劑偏好決定了研發重點。

診所和醫院需要可靠的藥品供應、監管文件以及通常更大包裝的藥品，而家庭護理機構則更注重易用性、患者依從性和便捷的配藥方式。按劑型分類，注射劑仍然是急性住院患者的主要需求，口服片劑則在門診處方中佔據主導地位，而透皮貼片因其能夠持續控制症狀並提高耐受性而日益受到青睞。分銷管道進一步影響市場准入：醫院藥房必須應對機構處方集和集團採購的動態變化，在線藥屋主打便捷性和直接面向經皮的履約，而零售藥房則提供便利的購買管道和藥劑師主導的諮詢服務。每個管道還包含不同層級的細分市場，需要量身定做的商業性和監管策略。

了解這些細分維度，可以讓公司根據每個客戶群的具體需求和決策促進因素，調整其研發、監管申報和商業性策略，從而提高成功採用和長期留存的幾率。

比較美洲、歐洲、中東和非洲以及亞太地區影響監管路徑、供應鏈最佳化和商業化策略的區域動態

區域動態將對東莨菪鹼產品的監管路徑、供應鏈決策和商業化策略產生重大影響。在美洲，結構化的醫院系統和整合的支付機制促進了循證醫學證據的產生與藥品納入醫保目錄之間的緊密聯繫，同時，數位化藥房的普及也持續擴大了直接面對消費者的用藥管道和遠端醫療的主導。這種環境有利於那些在患者依從性和耐受性方面展現出顯著優勢的新製劑的快速推廣應用。

在中東和非洲，監管環境的多樣性和不斷變化的報銷機制既帶來了機遇，也帶來了挑戰。製造商必須應對不同的核准要求和定價機制，通常優先在關鍵監管地區上市，同時也要準備臨床和衛生經濟學文件以支持更廣泛的市場准入。亞太新興市場擁有成本效益高的生產能力和不斷成長的基本藥物需求，但成功取決於量身定做的分銷策略和經銷商夥伴關係關係。

亞太地區匯聚了許多生物技術先進國家和快速發展的醫療衛生基礎設施。高產量契約製造生產商和完善的本地法規支持著產品研發的加速和區域供應的穩定。同時，門診服務的擴展和消費者健康意識的提高，推動了對易於使用的劑型（例如經皮吸收貼片和依從性最佳化的口服製劑）的需求。在所有地區，跨境監管協調和供應鏈多元化仍然是長期商業規劃的關鍵考量。

競爭格局分析，重點在於決定策略優勢的差異化配方、生產夥伴關係和分銷聯盟。

在東莨菪鹼生態系統中，競爭地位取決於一系列能力，從專有配方技術到大規模學名藥生產，再到專業器械整合。創新公司通常專注於緩釋性技術、經皮吸收貼片設計以及旨在推動處方醫生和支付方接受產品的綜合患者支援計畫。學名藥則專注於規模化生產、成本效益和快速回應監管要求，以滿足基本的臨床需求，他們往往在競標價格和分銷管道方面競爭。

受託製造廠商) 發揮著至關重要的作用，它們能夠幫助小型創新企業和大型非專利生產商擴大生產規模，同時確保品質合規性。在經皮製劑和複方組合藥物的開發中，與醫療設備專家建立策略夥伴關係日益重要，因為器材性能和人因工程設計對治療效果有顯著影響。此外，經銷商和數位藥局平台正逐漸成為重要的市場推廣合作夥伴，它們提供直接面向患者的管道和替代性履約模式，從而加快患者獲得治療的時間。

對於在該領域營運的公司而言，競爭優勢將來自於整合式策略，該策略結合了強力的監管證據、可靠的生產製造以及差異化的交付模式。將這些能力與有效的通路策略結合的公司，將更有能力滿足不斷變化的處方醫生期望和支付方需求。

針對東莨菪鹼相關人員的實際策略要務，重點在於供應鏈彈性、製劑創新、證據產生和整合通路最佳化。

產業領導者應優先採取一系列切實可行的措施，使開發平臺與營運韌性和商業性執行力保持一致。首先，實現原料藥和關鍵成分來源多元化，以降低跨境關稅和物流衝擊帶來的風險，同時識別冗餘供應商並加強供應商管治。其次，加快對經皮和控制釋放平台的投資，以提高患者依從性，並在與普通口服片劑的競爭中脫穎而出，而這些平台應有強力的臨床和人因工程證據支持。

第三，透過產生真實世界證據和衛生經濟學分析，深化與醫院處方集委員會和支付方的合作，以證明產品在特定應用情境中的價值。第四，透過將數位化管道整合到商業模式中，直接掌握病患需求，並促進依從性計畫的實施，進而提升病患療效和資料收集效率。第五，透過與合約研發生產機構（CDMO）和醫療器材專家夥伴關係，建立靈活的生產能力，以便在滿足不斷變化的需求的同時，快速擴大生產規模，並符合監管要求。

透過並行執行這些優先事項，公司可以降低營運風險，提高其產品組合的市場相關性，並創造能夠引起臨床醫生、支付者和最終用戶共鳴的差異化優勢。

透過結合主要相關人員訪談、監管文獻綜述、專利分析和供應鏈情境規劃的強力混合方法研究途徑，獲得可操作的洞見。

本執行摘要的分析綜合了第一手和第二手研究，旨在確保其相關性和實用性。第一手資料包括對臨床醫生、採購負責人、監管專家和生產主管進行的結構化訪談，以了解當前的決策促進因素、痛點和採納門檻。第二手研究包括審查監管指南、同行評審的臨床文獻、專利申請和產品標籤，以揭示臨床背景和配方趨勢。

補充分析包括供應鏈圖譜繪製和情境規劃，以評估貿易和關稅變化的影響。為確保資料完整性，訪談內容與已記錄的監管和臨床資訊來源進行交叉核對，並結合多方相關人員的觀點進行三角驗證，以減少偏差。這種混合通訊協定確保了研究結果基於當前實踐，並能為研發人員、製造商和商業團隊的實際策略決策提供參考。

本文全面分析了臨床需求交付創新和靈活營運如何決定莨菪鹼相關人員的成功軌跡。

東莨菪鹼的未來將由臨床需求、給藥創新和供應鏈韌性三者交互作用決定。該化合物已確立的治療作用為其提供了穩定的基礎，但競爭優勢將取決於相關人員如何有效地將製劑創新和循證醫學證據轉化為可及、可靠的產品。隨著醫療服務模式轉向以門診病人為中心的模式轉變，經皮和緩釋性因其依從性和耐受性優勢而備受關注。

同時，地緣政治和貿易趨勢凸顯了多元化採購和彈性生產安排的必要性。能夠預見採購中斷並使其商業策略與監管機構和支付方期望相符的公司，將能夠維持市場准入和相關性。總之，在莨菪鹼領域取得成功，需要研發、生產、監管和商業職能的整合執行，以提供差異化、可靠的療法，滿足臨床醫生和患者不斷變化的需求。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在新興市場擴大丁溴烷非專利藥的供應，以滿足對成本敏感的消費者需求。
  • 越來越多的臨床試驗正在評估長效製劑治療大腸激躁症的療效
  • 將氫溴酸東莨菪鹼輸送系統與智慧患者監測技術結合，以提高患者依從性
  • 在探險旅遊和郵輪產業中，東莨菪鹼用於預防暈動病的仿單標示外用藥日益增加。
  • 領先的製藥公司與生技公司建立策略夥伴關係關係，共同開發具有更高生物有效性的經皮東莨菪鹼貼片。
  • 針對功能性胃腸疾病的新型東莨菪鹼聯合治療的監管核准加速

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依品牌類型分類的東莨菪鹼市場

  • 品牌
  • 非專利的

9. 依應用分類的東莨菪鹼市場

  • 胃腸道疾病
  • 暈動病

第10章 以最終用戶分類的東莨菪鹼市場

  • 診所
  • 居家醫療
  • 醫院

第11章 以劑型分類的東莨菪鹼市場

  • 注射液
  • 口服錠劑
  • 經皮吸收貼片

第12章 依通路分類的東莨菪鹼市場

  • 醫院藥房
    • 政府醫院藥房
    • 私立醫院藥房
  • 網路藥房
    • 行動應用
    • 僅限網路的入口網站
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第13章 各地區東莨菪鹼市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 依組別分類的東莨菪鹼市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國東莨菪鹼市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Hikma Pharmaceuticals PLC
    • Sandoz International GmbH
    • Glenmark Pharmaceuticals Ltd.
    • Wockhardt Ltd.
    • Pfizer Inc.
Product Code: MRR-AD517FAAA7B7

The Hyoscine Market is projected to grow by USD 668.05 million at a CAGR of 4.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 460.41 million
Estimated Year [2025] USD 482.18 million
Forecast Year [2032] USD 668.05 million
CAGR (%) 4.76%

A concise orientation to hyoscine's clinical utility formulation evolution and supply chain dynamics shaping stakeholder priorities and strategic planning

Hyoscine occupies a distinct clinical niche that spans prevention of motion sickness to management of gastrointestinal spasm and perioperative secretions. Clinicians value the compound for its anticholinergic properties, which modulate vestibular and gastrointestinal pathways; formulators and manufacturers, meanwhile, are navigating an evolving landscape of delivery technologies, regulatory expectations, and channel dynamics. In recent years, attention has shifted from simple dose forms toward patient-centric options that balance efficacy with tolerability and convenience.

As clinical practice increasingly emphasizes outpatient care and home-based management, hyoscine's relevance in ambulatory settings has risen. Simultaneously, innovations in transdermal and controlled-release formulations respond to adherence challenges and profile improvements requested by prescribers. These forces create both opportunities and obligations for developers to demonstrate consistent product quality, robust pharmacovigilance, and alignment with evolving payer and hospital procurement priorities. Consequently, stakeholders must integrate clinical, commercial, and regulatory perspectives to maintain competitive positioning.

Transitioning from traditional supply chains to more resilient, diversified networks has become a strategic imperative. Manufacturers and distributors are recalibrating operations to ensure uninterrupted access to active pharmaceutical ingredient sources and packaging materials. This introductory overview frames the remainder of the executive summary by underscoring the interplay of therapeutic utility, formulation trends, and supply-side resilience that defines the current hyoscine landscape.

How technological advances regulatory tightening and shifts in distribution channels are reshaping product development commercial models and competitive advantage

The hyoscine landscape is undergoing transformative shifts driven by technology, regulatory focus, and changing care delivery models. Novel transdermal patch designs and long-acting injectable research reflect a broader industry pivot toward extended-release and non-oral delivery platforms that improve adherence and reduce systemic side effects. Parallel to product innovation, regulators are placing greater emphasis on lifecycle data, real-world safety monitoring, and post-approval surveillance, prompting manufacturers to invest in pharmacovigilance infrastructure and quality systems.

On the commercial side, distribution channels are fragmenting; digital pharmacy platforms have accelerated patient access and altered purchasing behavior, while hospital procurement remains decisive for in-hospital and perioperative uses. At the same time, consolidation among contract development and manufacturing organizations reshapes where and how hyoscine formulations are produced, encouraging vertical integration and strategic partnerships that can shorten time-to-market.

Collectively, these trends are transforming competitive dynamics from simple price competition to differentiated offerings that emphasize patient experience, regulatory robustness, and supply resiliency. Firms that align innovation with pragmatic regulatory and distribution strategies will be better positioned to capitalize on shifts in prescribing patterns and care delivery.

Strategic supply chain realignment and procurement responses to United States tariff measures driving diversification nearshoring and resilience initiatives across the value chain

Tariff policies and trade measures introduced by the United States in 2025 have exerted pressure across pharmaceutical supply chains, particularly for products reliant on imported active pharmaceutical ingredients and specialized packaging. The cumulative effect has been a recalibration of procurement strategies as manufacturers seek to mitigate input-cost volatility without compromising quality or continuity of supply. In practice, this has accelerated efforts to diversify API sourcing, qualify secondary suppliers, and evaluate nearshoring options that reduce exposure to cross-border tariff risk.

In addition, procurement teams within hospitals and integrated health systems have reacted by tightening contract terms and sharpening supplier evaluation criteria to account for potential cost pass-throughs. These dynamics have encouraged closer collaboration between commercial teams and supply-chain functions, fostering scenario planning that prioritizes supply continuity and contract flexibility. Meanwhile, regulatory and customs clearance complexities have encouraged manufacturers to enhance documentation and compliance capabilities, reducing the risk of shipment delays that could disrupt inventory-sensitive care settings.

Importantly, the tariff environment has also elevated the strategic value of packaging and delivery innovations that reduce weight or reliance on imported components. Companies investing in such incremental innovations can achieve greater insulation from trade-policy volatility. Overall, the 2025 tariff measures functioned as a catalyst for strategic supply-chain refinement, stronger supplier governance, and an intensified focus on resilience and operational agility.

Actionable segmentation insights linking brand strategy clinical application end-user requirements dosage form preferences and distribution channel dynamics to commercial success

A nuanced segmentation approach clarifies where clinical demand, formulation innovation, and commercial focus converge. When analyzed by brand type, distinctions between branded and generic offerings drive divergent strategies: branded manufacturers emphasize differentiation through novel delivery systems and enhanced patient-support services, whereas generic players compete on cost, manufacturing efficiency, and distribution breadth. Based on application, demand varies between gastrointestinal disorder management and motion sickness prevention, with differing prescriber profiles, dosing regimens, and formulation preferences informing development priorities.

Different end users shape procurement and usage patterns; clinics and hospitals require reliable supply, regulatory documentation, and often larger volume packaging, while home care settings prioritize ease of use, patient adherence, and convenient dispensing. Across dosage forms, injectable solutions remain critical for acute inpatient needs, oral tablets are the mainstay for outpatient prescriptions, and transdermal patches are gaining traction for sustained symptom control and improved tolerability. Distribution channels further influence market access: hospital pharmacies must navigate institutional formularies and group purchasing dynamics, online pharmacies drive convenience and direct-to-patient fulfillment, and retail pharmacies offer accessibility and pharmacist-led counseling. Each channel also has layered sub-segments that require tailored commercial and regulatory approaches to optimize uptake and patient outcomes.

Understanding these segmentation vectors enables companies to align R&D, regulatory submissions, and commercial tactics with the specific requirements and decision drivers of each customer cohort, thereby enhancing the probability of successful adoption and long-term retention.

Comparative regional dynamics shaping regulatory pathways supply chain optimization and commercialization strategies across the Americas Europe Middle East Africa and Asia Pacific

Regional dynamics materially affect regulatory pathways, supply-chain decisions, and commercial strategies for hyoscine products. In the Americas, structured hospital systems and integrated payer mechanisms encourage strong alignment between evidence generation and formulary inclusion, while digital pharmacy adoption continues to expand direct-to-consumer access and telehealth-driven prescribing. This environment favors rapid dissemination of new formulations that demonstrate measurable benefits in adherence or tolerability.

Within Europe Middle East & Africa, regulatory heterogeneity and variable reimbursement landscapes create both opportunities and complexities. Manufacturers must navigate diverse approval requirements and pricing mechanisms, often prioritizing key regulatory jurisdictions for initial launches while building clinical and health-economic dossiers to support broader access. Emerging markets in the region may offer cost-effective manufacturing and growing demand for essential medicines, but success depends on tailored distribution strategies and partnerships with regional distributors.

Asia-Pacific presents a mix of advanced biotech hubs and rapidly evolving healthcare infrastructures. High-capacity contract manufacturers and increasing local regulatory sophistication support accelerated product development and regional supply. Simultaneously, expanding outpatient care and consumer health awareness are driving demand for user-friendly dosage forms such as transdermal patches and oral formulations optimized for adherence. Across all regions, cross-border regulatory harmonization efforts and supply-chain diversification remain pivotal considerations for long-term commercial planning.

Competitive landscape analysis emphasizing formulation differentiation manufacturing partnerships and distribution collaborations that determine strategic advantage

Competitive positioning in the hyoscine ecosystem is defined by a spectrum of capabilities that range from proprietary formulation expertise to high-volume generic manufacturing and specialized device integration. Innovator firms typically focus on sustained-release technologies, transdermal patch design, and integrated patient-support programs that bolster adoption among prescribers and payers. Generic manufacturers emphasize scale, cost-efficient production, and rapid regulatory pathways to meet baseline clinical demand, often competing on tender performance and distribution reach.

Contract development and manufacturing organizations play a pivotal role by enabling both small innovators and large generics to scale production while maintaining quality compliance. Strategic partnerships with medical-device specialists are increasingly important for transdermal and combination product development, where device performance and human factors design materially affect outcomes. Additionally, distributors and digital pharmacy platforms are emerging as influential go-to-market partners, offering direct channels to patients and alternative fulfillment models that can shorten time-to-treatment.

For companies operating in this space, competitive advantage derives from an integrated approach that combines robust regulatory evidence, manufacturing reliability, and differentiated delivery modalities. Firms that bridge these competencies with effective channel strategies will be better positioned to respond to evolving prescriber expectations and payer demands.

Practical strategic imperatives for hyoscine stakeholders focusing on supply resilience formulation innovation evidence generation and integrated channel optimization

Industry leaders should prioritize a set of pragmatic actions that align development pipelines with operational resilience and commercial execution. First, diversify API and critical component sourcing to reduce exposure to cross-border tariff and logistical shocks while qualifying redundant suppliers and strengthening supplier governance. Second, accelerate investment in transdermal and controlled-release platforms that improve patient adherence and create differentiation beyond commodity oral tablets, supported by robust clinical and human factors evidence.

Third, deepen engagement with hospital formulary committees and payers by generating real-world evidence and health-economic analyses that demonstrate value in targeted use cases. Fourth, integrate digital channels into commercial models to capture direct-to-patient demand and facilitate adherence programs, thereby enhancing patient outcomes and data capture. Fifth, establish flexible manufacturing arrangements through partnerships with CDMOs and device specialists to scale quickly in response to demand shifts while maintaining compliance with regulatory expectations.

By executing these priorities in parallel, organizations can reduce operational risk, increase the market relevance of their portfolios, and create defensible differentiation that resonates with clinicians, payers, and end users.

Robust mixed methods research approach combining primary stakeholder interviews regulatory literature review patent analysis and supply chain scenario planning for actionable insights

The analysis underpinning this executive summary synthesizes primary and secondary research methods designed to ensure validity and practical relevance. Primary inputs included structured interviews with clinicians, procurement leaders, regulatory experts, and manufacturing executives to capture contemporary decision drivers, pain points, and adoption thresholds. Secondary research comprised review of regulatory guidelines, peer-reviewed clinical literature, patent filings, and product labeling to establish clinical context and formulation trends.

Complementary analyses incorporated supply-chain mapping and scenario planning to assess the implications of trade and tariff changes, as well as a review of technology adoption patterns in delivery systems and digital distribution. Data integrity protocols included cross-verification of interview insights with documented regulatory and clinical sources, and triangulation across multiple stakeholder perspectives to reduce bias. This mixed-methods approach ensures that the findings are grounded in current practice and can inform pragmatic strategic decisions for developers, manufacturers, and commercial teams.

Synthesis of how clinical demand delivery innovation and resilient operations collectively define success trajectories for hyoscine stakeholders

Hyoscine's future will be shaped by an interplay of clinical needs, delivery innovation, and supply-chain resilience. The compound's established therapeutic roles provide a stable foundation, yet competitive advantage will increasingly depend on how effectively stakeholders translate formulation innovation and evidence generation into accessible, reliable products. As healthcare delivery shifts toward outpatient and patient-centered care, transdermal and sustained-release options are poised to capture attention for their adherence and tolerability benefits.

Concurrently, geopolitical and trade developments have highlighted the necessity of diversified sourcing and flexible manufacturing arrangements. Companies that anticipate procurement disruptions and align commercial strategies with regulatory and payer expectations will sustain access and relevance. In sum, success in the hyoscine space requires integrated execution across R&D, manufacturing, regulatory, and commercial functions to deliver differentiated, reliable therapeutics that meet evolving clinician and patient needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of generic hyoscine butylbromide formulations in emerging markets to meet cost-sensitive consumer demand
  • 5.2. Increasing clinical trials evaluating long-acting hyoscine formulations for irritable bowel syndrome management
  • 5.3. Integration of hyoscine hydrobromide delivery systems with patient smart monitoring technologies to improve adherence
  • 5.4. Growing off-label use of hyoscine for motion sickness prevention in adventure tourism and cruise industries
  • 5.5. Strategic partnerships between pharmaceutical giants and biotech firms to develop transdermal hyoscine patches with enhanced bioavailability
  • 5.6. Regulatory approvals accelerating for novel hyoscine combination therapies targeting functional gastrointestinal disorders

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hyoscine Market, by Brand Type

  • 8.1. Branded
  • 8.2. Generic

9. Hyoscine Market, by Application

  • 9.1. Gastrointestinal Disorders
  • 9.2. Motion Sickness

10. Hyoscine Market, by End User

  • 10.1. Clinics
  • 10.2. Home Care
  • 10.3. Hospitals

11. Hyoscine Market, by Dosage Form

  • 11.1. Injectable Solution
  • 11.2. Oral Tablets
  • 11.3. Transdermal Patch

12. Hyoscine Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
    • 12.1.1. Government Hospital Pharmacy
    • 12.1.2. Private Hospital Pharmacy
  • 12.2. Online Pharmacy
    • 12.2.1. Mobile App
    • 12.2.2. Web Only Portal
  • 12.3. Retail Pharmacy
    • 12.3.1. Chain Pharmacy
    • 12.3.2. Independent Pharmacy

13. Hyoscine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hyoscine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hyoscine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. Teva Pharmaceutical Industries Ltd.
    • 16.3.3. Viatris Inc.
    • 16.3.4. Dr. Reddy's Laboratories Ltd.
    • 16.3.5. Sun Pharmaceutical Industries Ltd.
    • 16.3.6. Hikma Pharmaceuticals PLC
    • 16.3.7. Sandoz International GmbH
    • 16.3.8. Glenmark Pharmaceuticals Ltd.
    • 16.3.9. Wockhardt Ltd.
    • 16.3.10. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HYOSCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HYOSCINE MARKET SIZE, BY BRAND TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HYOSCINE MARKET SIZE, BY BRAND TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HYOSCINE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HYOSCINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HYOSCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HYOSCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HYOSCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HYOSCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HYOSCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HYOSCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HYOSCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HYOSCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HYOSCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HYOSCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HYOSCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HYOSCINE MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HYOSCINE MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HYOSCINE MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HYOSCINE MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYOSCINE MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HYOSCINE MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HYOSCINE MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HYOSCINE MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HYOSCINE MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HYOSCINE MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYOSCINE MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HYOSCINE MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYOSCINE MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HYOSCINE MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYOSCINE MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HYOSCINE MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYOSCINE MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HYOSCINE MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HYOSCINE MARKET SIZE, BY MOTION SICKNESS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HYOSCINE MARKET SIZE, BY MOTION SICKNESS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HYOSCINE MARKET SIZE, BY MOTION SICKNESS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HYOSCINE MARKET SIZE, BY MOTION SICKNESS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HYOSCINE MARKET SIZE, BY MOTION SICKNESS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HYOSCINE MARKET SIZE, BY MOTION SICKNESS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYOSCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HYOSCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYOSCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HYOSCINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYOSCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HYOSCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HYOSCINE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HYOSCINE MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYOSCINE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HYOSCINE MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HYOSCINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HYOSCINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HYOSCINE MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HYOSCINE MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HYOSCINE MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HYOSCINE MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HYOSCINE MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HYOSCINE MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HYOSCINE MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HYOSCINE MARKET SIZE, BY ORAL TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HYOSCINE MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HYOSCINE MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HYOSCINE MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HYOSCINE MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HYOSCINE MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HYOSCINE MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HYOSCINE MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HYOSCINE MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HYOSCINE MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HYOSCINE MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HYOSCINE MARKET SIZE, BY GOVERNMENT HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HYOSCINE MARKET SIZE, BY GOVERNMENT HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HYOSCINE MARKET SIZE, BY GOVERNMENT HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HYOSCINE MARKET SIZE, BY GOVERNMENT HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HYOSCINE MARKET SIZE, BY GOVERNMENT HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HYOSCINE MARKET SIZE, BY GOVERNMENT HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HYOSCINE MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HYOSCINE MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HYOSCINE MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HYOSCINE MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HYOSCINE MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HYOSCINE MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HYOSCINE MARKET SIZE, BY MOBILE APP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HYOSCINE MARKET SIZE, BY MOBILE APP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HYOSCINE MARKET SIZE, BY MOBILE APP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HYOSCINE MARKET SIZE, BY MOBILE APP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HYOSCINE MARKET SIZE, BY MOBILE APP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HYOSCINE MARKET SIZE, BY MOBILE APP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HYOSCINE MARKET SIZE, BY WEB ONLY PORTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HYOSCINE MARKET SIZE, BY WEB ONLY PORTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HYOSCINE MARKET SIZE, BY WEB ONLY PORTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HYOSCINE MARKET SIZE, BY WEB ONLY PORTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HYOSCINE MARKET SIZE, BY WEB ONLY PORTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HYOSCINE MARKET SIZE, BY WEB ONLY PORTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HYOSCINE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HYOSCINE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HYOSCINE MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HYOSCINE MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HYOSCINE MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HYOSCINE MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HYOSCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HYOSCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HYOSCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HYOSCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HYOSCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HYOSCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HYOSCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HYOSCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS HYOSCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS HYOSCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL HYOSCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL HYOSCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 301. GCC HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GCC HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GCC HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. GCC HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. GCC HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 306. GCC HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 307. GCC HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. GCC HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. GCC HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 310. GCC HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 311. GCC HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. GCC HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. GCC HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 315. GCC HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 316. GCC HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 317. GCC HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 318. GCC HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. BRICS HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. BRICS HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 342. BRICS HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 352. BRICS HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 353. BRICS HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 354. BRICS HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 355. G7 HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 356. G7 HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 357. G7 HYOSCINE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
  • TABLE 358. G7 HYOSCINE MARKET SIZE, BY BRAND TYPE, 2025-2032 (USD MILLION)
  • TABLE 359. G7 HYOSCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 360. G7 HYOSCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 361. G7 HYOSCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 362. G7 HYOSCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 363. G7 HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 364. G7 HYOSCINE MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 365. G7 HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 366. G7 HYOSCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 367. G7 HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 368. G7 HYOSCINE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 369. G7 HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 370. G7 HYOSCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 371. G7 HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 372. G7 HYOSCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 373. NATO HYOSCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 374. NATO HYOSCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 375. NATO HYOSCINE MARKET SIZE, BY BRAND TY